Merck
4Q Revenues: $13.8 billion (+2%)
4Q Earnings: $3.0 billion (-21%)
FY Revenues: $59.3 billion (+22%)
FY Earnings: $14.5 billion (+18%)
Comments: Pharmaceutical sales were $12.2 billion in the quarter, up 1% and $52.0 billion for the year, up 22%. Keytruda sales were $5.5 billion in the quarter, up 19% and $20.9 billion for the year, up 22%. GARDASIL sales were $1.5 billion int he quarter, down 4% and $6.9 billion for the year, up 22%. LAGEVRIO sales were $825 million in the quarter, down 13% and $5.7 billion for the year, >100%. JANUVIA / JANUMET sales were $913 million in the quarter, down 34%, and $4.5 billion for the year, down 15%. PROQUAD, M-M-R II and VARIVAX sales were $26 million in the quarter, up 3%, and $2.2 billion for the year, up 5%. BRIDION sales were $441 million in the quarter, up 1% and $1.7 billion for the year, up 10%.  ROTATEQ sales were down 35% to $139 million in the quarter, and down 3% for the year to $783 million. SIMPONI sales were down 19% in the quarter to $166 million and down 14% for the year to $706 million.
 
Pharmaceutical sales growth was partially offset by lower sales of JANUVIA and JANUMET for the treatment of type 2 diabetes, primarily reflecting generic competition, lower demand and net pricing in the U.S.
 
Sales of LAGEVRIO (molnupiravir), an investigational oral antiviral COVID-19 medicine, decreased 13% to $825 million in the quarter. Excluding the unfavorable impact of foreign exchange, sales increased 2%, primarily driven by strong growth in Japan and the U.K. and the launch in Australia, offset by a decline in the U.S.